Tags

Type your tag names separated by a space and hit enter

A 0.05% cetyl pyridinium chloride/0.05% chlorhexidine mouth rinse during maintenance phase after initial periodontal therapy.
J Clin Periodontol 2005; 32(4):390-400JC

Abstract

BACKGROUND

Chlorhexidine (CHX) mouth rinse/spray can still be considered the gold standard in the chemical prevention of plaque formation and development of gingivitis. The product unfortunately has some side effects, such as extrinsic tooth staining, poor taste, taste disturbance, sensitivity changes in tongue, pain and irritation because of the alcohol content. These side effects led to the search of new formulations.

METHODS

In this double-blind, randomized, long-term, parallel study, 48 moderate periodontitis patients rinsed for 6 months (starting immediately after a "one-stage, full-mouth" disinfection) with one of the following products: CHX 0.2%+alcohol (Corsodyl), CHX 0.05%+ cetyl pyridinium chloride (CPC) 0.05% and no alcohol (Perio-Aid Maintenance, a new formulation), or the placebo of the latter. After 1, 3 and 6 months a series of clinical and microbiological parameters were recorded for the supra- and subgingival area as well as for saliva.

RESULTS

Although there was a significant treatment impact (mechanical debridement) in all groups, both CHX solutions further decreased both plaque and gingivitis indices (p<0.001 and p<0.05, respectively), when compared with placebo. This was also reflected by additional reductions in the number of CFU/ml of aerobic and especially anaerobic species and by a suppression of Streptococcus mutans (versus an overgrowth for the placebo), in all niches. Differences between both CHX solutions were never encountered. The subjective ratings were slightly in favour of the new CHX-CPC formulation when compared with the other CHX-alcohol formulation, especially for taste of the product (p<0.05), but less impressive for the staining of teeth and tongue.

CONCLUSIONS

The results of this study demonstrated the potential of a new CHX 0.05%+CPC 0.05% non-alcoholic formulation as an effective antiplaque agent for long-term use with reduced subjective side effects.

Authors+Show Affiliations

Department of Periodontology, Oral Pathology and Maxillo-Facial Surgery, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15811057

Citation

Quirynen, Marc, et al. "A 0.05% Cetyl Pyridinium Chloride/0.05% Chlorhexidine Mouth Rinse During Maintenance Phase After Initial Periodontal Therapy." Journal of Clinical Periodontology, vol. 32, no. 4, 2005, pp. 390-400.
Quirynen M, Soers C, Desnyder M, et al. A 0.05% cetyl pyridinium chloride/0.05% chlorhexidine mouth rinse during maintenance phase after initial periodontal therapy. J Clin Periodontol. 2005;32(4):390-400.
Quirynen, M., Soers, C., Desnyder, M., Dekeyser, C., Pauwels, M., & van Steenberghe, D. (2005). A 0.05% cetyl pyridinium chloride/0.05% chlorhexidine mouth rinse during maintenance phase after initial periodontal therapy. Journal of Clinical Periodontology, 32(4), pp. 390-400.
Quirynen M, et al. A 0.05% Cetyl Pyridinium Chloride/0.05% Chlorhexidine Mouth Rinse During Maintenance Phase After Initial Periodontal Therapy. J Clin Periodontol. 2005;32(4):390-400. PubMed PMID: 15811057.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A 0.05% cetyl pyridinium chloride/0.05% chlorhexidine mouth rinse during maintenance phase after initial periodontal therapy. AU - Quirynen,Marc, AU - Soers,Catherine, AU - Desnyder,Mandy, AU - Dekeyser,Christel, AU - Pauwels,Martine, AU - van Steenberghe,Daniel, PY - 2005/4/7/pubmed PY - 2005/5/17/medline PY - 2005/4/7/entrez SP - 390 EP - 400 JF - Journal of clinical periodontology JO - J. Clin. Periodontol. VL - 32 IS - 4 N2 - BACKGROUND: Chlorhexidine (CHX) mouth rinse/spray can still be considered the gold standard in the chemical prevention of plaque formation and development of gingivitis. The product unfortunately has some side effects, such as extrinsic tooth staining, poor taste, taste disturbance, sensitivity changes in tongue, pain and irritation because of the alcohol content. These side effects led to the search of new formulations. METHODS: In this double-blind, randomized, long-term, parallel study, 48 moderate periodontitis patients rinsed for 6 months (starting immediately after a "one-stage, full-mouth" disinfection) with one of the following products: CHX 0.2%+alcohol (Corsodyl), CHX 0.05%+ cetyl pyridinium chloride (CPC) 0.05% and no alcohol (Perio-Aid Maintenance, a new formulation), or the placebo of the latter. After 1, 3 and 6 months a series of clinical and microbiological parameters were recorded for the supra- and subgingival area as well as for saliva. RESULTS: Although there was a significant treatment impact (mechanical debridement) in all groups, both CHX solutions further decreased both plaque and gingivitis indices (p<0.001 and p<0.05, respectively), when compared with placebo. This was also reflected by additional reductions in the number of CFU/ml of aerobic and especially anaerobic species and by a suppression of Streptococcus mutans (versus an overgrowth for the placebo), in all niches. Differences between both CHX solutions were never encountered. The subjective ratings were slightly in favour of the new CHX-CPC formulation when compared with the other CHX-alcohol formulation, especially for taste of the product (p<0.05), but less impressive for the staining of teeth and tongue. CONCLUSIONS: The results of this study demonstrated the potential of a new CHX 0.05%+CPC 0.05% non-alcoholic formulation as an effective antiplaque agent for long-term use with reduced subjective side effects. SN - 0303-6979 UR - https://www.unboundmedicine.com/medline/citation/15811057/A_0_05_cetyl_pyridinium_chloride/0_05_chlorhexidine_mouth_rinse_during_maintenance_phase_after_initial_periodontal_therapy_ L2 - https://doi.org/10.1111/j.1600-051X.2005.00685.x DB - PRIME DP - Unbound Medicine ER -